RNAZ transcodetherapeutics.com: Bozor kapitallashuvining balans qiymatiga nisbati

RNAZ (TransCode Therapeutics Inc.) - kompaniyaning tovar belgisi

TransCode Therapeutics (RNAZ) dumpingga qarshi patentlar bilan himoyalangan RNA-ga asoslangan saratonga qarshi dori vositalarini ishlab chiqadi. Ushbu bozor qiymatining bukhgalteriya qiymatiga nisbati grafigi aktivlar baholash dinamikasini vizuallashtiradi, bunda -0.06 ushbu metrikaning bazaviy ko'rsatkichini aks ettiradi. Operatsion pul oqimi hali boshlanmaganligi sababli, joriy impuls investitsiyalar hisobiga ta'minlanmoqda. Ishlab chiqish jarayoni iqtisodiy sikllardan mustaqil qolmoqda va faqat kapitalning mavjudligiga bog'liqdir.

transcodetherapeutics.com (RNAZ): Kapitallashuvning balans qiymatiga nisbati 04.07.2022dan 26.10.2026gacha

TransCode Therapeutics (RNAZ) moliyaviy va bozor koʻrsatkichlari kesimi

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari transcodetherapeutics.com|RNAZ - Prognoz darajalari grafigi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi TransCode|RNAZ - Biznes qiymati
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya uchun sof aktivlar TransCode Therapeutics|RNAZ - Buxgalteriya kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati transcodetherapeutics.com|RNAZ - Kompaniyaning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning xususiy kapitalga nisbati TransCode Therapeutics|RNAZ - Uzoq muddatli kreditlarning kapitalga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati transcodetherapeutics.com|RNAZ - Jamlangan qarz majburiyatlari|Balans kapitallashuviga qarzlar TransCode
Kompaniyaning dastlabki tahlili:TransCode Therapeutics Inc. - RNAZ
transcodetherapeutics.com seriyali mahsuloti

Ushbu ko'rsatkich biznesning bozor qiymatining uning sof aktivlaridan yuqoriligini o'lchaydi. Biofarmatsevtika innovatori TransCode Therapeutics (RNAZ) uchun ushbu farq TTX platformasining intellektual salohiyatining kapitalizatsiyasini aks ettiradi. Kompaniyaning bozor kapitalizatsiyasining uning balans qiymatiga nisbatini tahlil qilish orqali investorlarning R&D loyihalaridan kutayotgan natijalarini baholash mumkin. Ko'paytiruvchining o'sishi bozorning onkologiya sohasidagi texnologik yetakchiligiga bo'lgan ishonchini tasdiqlaydi, ekstremal qiymatlar esa aktivning haddan tashqari sotib olinganligidan dalolat beradi.

Toʻgʻridan-toʻgʻri raqobatchilar

Kapitallashuvning sof aktivlarga nisbati Tempus Labs (TEM)|qiagen.com (QGEN) - Sof aktivlarga nisbatan bozor kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati Ionis (IONS)|Kapitallashuvning balans qiymatiga nisbati RGEN|Bozor qiymatining balans qiymatiga nisbati Avidity RNA|Kapitallashuvning balans qiymatiga nisbati CRISPR (CRSP)|Bozor kapitallashuvining balans qiymatiga nisbati WGS (GeneDx Holdings Corp.)|RARE - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati Beam Therapeutics BEAM|SRPT: Bozor kapitallashuvining balans qiymatiga multiplikatori|Bozor qiymatining balans qiymatiga nisbati Twist Bio TWST|10x (TXG) - Balans qiymatiga nisbatan bozor qiymati|NTLA (Intellia Therapeutics) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati STOK|Bozor qiymatining balans qiymatiga nisbati BioLife Solutions BLFS|Kapitallashuvning balans qiymatiga nisbati WVE (Wave Life Sciences Ltd)|Bozor qiymatining balans qiymatiga nisbati MAZE|Balans qiymatiga nisbatan bozor kapitallashuvi Sionna Corp SION|PRME: Bozor kapitallashuvining balans qiymatiga nisbati|TSHA: Kapitallashuvning sof aktivlarga nisbati|Bozor qiymatining balans qiymatiga nisbati QURE|MeiraGTx Holdings (MGTX) - Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor kapitallashuvining balans qiymatiga nisbati Regenxbio (RGNX)|Kapitallashuvning balans qiymatiga nisbati Solid Corp|Ocugen, Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti pacb.com PACB|Kapitallashuvning sof aktivlarga nisbati Benitec Biopharma|DSGN - Balans qiymatiga nisbatan bozor qiymati|Kapitallashuvning sof aktivlarga nisbati Rocket Pharmaceuticals Inc RCKT|FDMT - Bozor kapitallashuvining balans qiymatiga multiplikatori|Bozor kapitallashuvining balans qiymatiga nisbati lexeotx.com LXEO|Korro Bio (KRRO) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati EDIT (Editas Medicine)|Bozor qiymatining balans qiymatiga koeffitsiyenti SLN|ProQR Therapeutics N.V. (PRQR) - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati codexis.com (CDXS)|Bozor kapitallashuvining balans qiymatiga nisbati SGMO (Sangamo Therapeutics)|Nautilus Biotechnology, Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati Metagenomi|DTIL - Sof aktivlarga nisbatan bozor kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati GBIO|Bozor qiymatining balans qiymatiga koeffitsiyenti Boundless Bio Inc|XCUR (Exicure Inc.) - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati Celsion Corporation (IMNN)|Kapitallashuvning sof aktivlarga nisbati Phio Pharmaceuticals|Bozor kapitallashuvining balans qiymatiga multiplikatori mustangbio.com (MBIO)|Bozor kapitallashuvining balans qiymatiga nisbati BNGO|Balans qiymatiga nisbatan bozor kapitallashuvi Applied DNA Corp APDN|BLUE: Bozor kapitallashuvining balans qiymatiga nisbati|IPA: Kapitallashuvning sof aktivlarga nisbati|Omega Therapeutics, Inc. - Bozor qiymatining balans qiymatiga nisbati|OMIC (Singular Genomics Systems, Inc.) - Balans qiymatiga nisbatan bozor kapitallashuvi|RGLS - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati SYRS|Bozor qiymatining balans qiymatiga nisbati Telesis Bio, Inc. TBIO|Kapitallashuvning balans qiymatiga nisbati traconpharma.com (TCON)|Bozor kapitallashuvining balans qiymatiga nisbati UBX (Unity Biotechnology, Inc.)